By contrast, the Dow Jones Prescription yasmin Average is down.
Alert me when articles match as these words. In past economic downturns, Skin test tuberculin looking for cover from falling share prices could always run to health care stocks. Com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue.
Rose care Stock Refuge No Refuge at All Sunday May, am ET.
In past economic downturns, investors looking for cover from falling share prices could always run to health care stocks. This year, though, that classic safe haven appears worse than the storm.
By richard, the Dow Jones Industrial Average is down. Last week, and the Nasdaq Composite Index is down.
Humana, one of last year’s top performing health insurers, is down this year, while WellPoint and Health Net have dropped and, respectively. On top of that, the Loans with bad credit election season adds another layer of uncertainty, though the actual fundamentals are more in question than any potential policy change, Mr. The shift is putting pressure on different health care sectors in different ways. WellPoint, which has lowered its profit forecast already twice this year, has said more small businesses facing hard times are dropping or cutting back coverage. It puts a real squeeze on their business model, says William Rutherford of Rutherford Investment Management in Portland, Ore. Who says he has shied away from the managed care sector.
Companies with fast growing consumer health franchises not affected by health insurance, such as aesthetic lasers and eyesight improvement surgery, are more directly vulnerable to the economy. Even companies with established drug portfolios face higher risks than before. After several drug scares and recalls, such as that of Merck’s painkiller Vioxx, drug regulators have been responding more aggressively to safety concerns. Investors say they still see plenty of defensive plays in certain niches and, after so many price plunges, a lot of value, too.
Though Barr’s first quarter sales and earnings were below expectations, it remains well positioned to take advantage of growing generic drug use and recently won approval to market a version of Yasmin, a popular oral contraceptive. A common favorite among investors is, which develops and supplies digital mammography and other advanced imaging systems for women’s health needs. Big biotech looks more promising than big pharma, says David Smith, chief investment officer for Rockland Trust’s Investment Management Group in Massachusetts. Has a broad portfolio of drugs with little patent expiration risk and more in development, he says.
.
Interested in Nike serbia? Right place for it!